TEVA (TEVA)
Teva Pharmaceutical Industries Ltd. - Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-749) for the Once-Monthly Treatment of Schizophrenia in Adults
Teva Pharmaceutical Industries Ltd. - Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-749) for the Once-Monthly Treatment of Schizophrenia in Adults
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General